PRESTRELSKI STEVEN 4
4 · Xeris Biopharma Holdings, Inc. · Filed Feb 1, 2023
Insider Transaction Report
Form 4
PRESTRELSKI STEVEN
Chief Scientific Officer
Transactions
- Award
Common Stock
2023-01-31+150,000→ 719,780 total
Footnotes (1)
- [F1]These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.